Use of aldosterone antagonists to inhibit myocardial fibrosis
CA 2177848 A1 · Owner: Weber, Karl T. · Inventors: Weber, Karl T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention discloses a method of using an aldosterone antagonist such as spironolactone and epoxymexrenone at a dosage, which does not disrupt a patient's normal electrolyte and water-retention balance to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 1, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 1, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 1, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.